Biocon Limited has informed the Exchange regarding a press release dated April 21, 2026, titled "Biocon Receives Health Canada Approval of Bosaya (Denosumab) and Vevzuo (Denosumab), Biosimilars to Prolia® and Xgeva®".
Press Release Apr 21 2026
Filed with NSE · · 5 pages · English
Release
Earlier from Biocon
- Biocon Receives Health Canada Approval of Bosaya™ (Denosumab) and Vevzuo™ (Denosumab), Biosimilars to Prolia® and Xgeva®
- Press Release Apr 07 2026
- Shreehas Tambe Appointed CEO and Managing Director of Biocon Limited, Effective April 1, 2026
- Press Release Mar 27 2026
- Press Release Feb 24 2026
Later from Biocon
- Press Release May 07 2026
- Biocon Limited Press Release Jun 24 2026
- Biocon Limited Press Release Jul 09 2026
- Biocon Announces Publication of Pivotal Clinical Data Supporting Effectiveness of Yesafili™, a Biosimilar to Eylea® (Aflibercept)
- Biocon Announces Publication of Pivotal Clinical Data Supporting Effectiveness of Yesafili, a Biosimilar to Eylea
Follow Biocon into a list and get an email when it puts out news.
Follow Biocon